Paper41347637
Model-Based Meta-Analysis With MonolixSuite: A Tutorial for Longitudinal Categorical and Continuous Data.
Bracis C and 5 others. CPT Pharmacometrics Syst Pharmacol, 2026. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Model-Based Meta-Analysis With MonolixSuite: A Tutorial for Longitudinal Categorical and Continuous Data. Papers, record 41347637. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41347637
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Model-Based Meta-Analysis With MonolixSuite: A Tutorial for Longitudinal Categorical and Continuous Data.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Meta-Analysis as Topic | Major topic |
| Models, Statistical | Major topic |
| Humans | |
| Arthritis, Rheumatoid | |
| Osteoarthritis | |
| Antibodies, Monoclonal, Humanized | |
| Naproxen | |
| Longitudinal Studies | |
| Drug Development |
Source PubMed
References29
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33782057 | The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. | BMJ | 2021 | https://conductscience.org/library/papers/33782057 | PubMed |
| 2 | 26933516 | The Many Flavors of Model-Based Meta-Analysis: Part I-Introduction and Landmark Data. | CPT Pharmacometrics Syst Pharmacol | 2016 | https://conductscience.org/library/papers/26933516 | PubMed |
| 3 | 21618201 | Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. | Arthritis Rheum | 2011 | https://conductscience.org/library/papers/21618201 | PubMed |
| 4 | 22048227 | A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. | Clin Pharmacol Ther | 2011 | https://conductscience.org/library/papers/22048227 | PubMed |
| 5 | 21088872 | The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects. | J Pharmacokinet Pharmacodyn | 2011 | https://conductscience.org/library/papers/21088872 | PubMed |
| 6 | 22760002 | Longitudinal model-based meta-analysis in rheumatoid arthritis: an application toward model-based drug development. | Clin Pharmacol Ther | 2012 | https://conductscience.org/library/papers/22760002 | PubMed |
| 7 | 34534661 | Epidemiology of osteoarthritis. | Osteoarthritis Cartilage | 2022 | https://conductscience.org/library/papers/34534661 | PubMed |
| 8 | 22089340 | Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond. | Clin Pharmacol Ther | 2011 | https://conductscience.org/library/papers/22089340 | PubMed |
| 9 | 38724461 | Application and Quality of Model-Based Meta-Analysis in Pharmaceutical Research: A Systematic Cross-Sectional Analysis and Practical Considerations. | Clin Pharmacol Ther | 2024 | https://conductscience.org/library/papers/38724461 | PubMed |
| 10 | 22910485 | Model-based meta-analysis: an important tool for making quantitative decisions during drug development. | Clin Pharmacol Ther | 2012 | https://conductscience.org/library/papers/22910485 | PubMed |
| 11 | 41347637 | Model-Based Meta-Analysis With MonolixSuite: A Tutorial for Longitudinal Categorical and Continuous Data. | CPT Pharmacometrics Syst Pharmacol | 2026 | https://conductscience.org/library/papers/41347637 | PubMed |
| 12 | 7779114 | American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. | Arthritis Rheum | 1995 | https://conductscience.org/library/papers/7779114 | PubMed |
| 13 | 18055472 | Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. | Ann Rheum Dis | 2008 | https://conductscience.org/library/papers/18055472 | PubMed |
| 14 | 12528101 | Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. | Arthritis Rheum | 2003 | https://conductscience.org/library/papers/12528101 | PubMed |
| 15 | 16052582 | Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. | Arthritis Rheum | 2005 | https://conductscience.org/library/papers/16052582 | PubMed |
| 16 | 35174432 | Applications of Model-Based Meta-Analysis in Drug Development. | Pharm Res | 2022 | https://conductscience.org/library/papers/35174432 | PubMed |
| 17 | 36631827 | Concept and application of the probability of pharmacological success (PoPS) as a decision tool in drug development: a position paper. | J Transl Med | 2023 | https://conductscience.org/library/papers/36631827 | PubMed |
| 18 | 15146409 | Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. | Arthritis Rheum | 2004 | https://conductscience.org/library/papers/15146409 | PubMed |
| 19 | 30993679 | Model-Based Meta-Analysis: Optimizing Research, Development, and Utilization of Therapeutics Using the Totality of Evidence. | Clin Pharmacol Ther | 2019 | https://conductscience.org/library/papers/30993679 | PubMed |
| 20 | 20358280 | Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation. | J Pharmacokinet Pharmacodyn | 2010 | https://conductscience.org/library/papers/20358280 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42438069 | Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis. | CPT Pharmacometrics Syst Pharmacol | 2026 | https://conductscience.org/library/papers/42438069 | PubMed |
| 41867226 | When Survival Improves But Quality of Life Does Not: A Model-Based Meta-Analysis of Immune Checkpoint Inhibitors. | medRxiv | 2026 | https://conductscience.org/library/papers/41867226 | PubMed |
| 41754991 | Systematic Review and Model-Based Meta-Analysis of Targeted Drugs for Systemic Sclerosis. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/41754991 | PubMed |
| 41347637 | Model-Based Meta-Analysis With MonolixSuite: A Tutorial for Longitudinal Categorical and Continuous Data. | CPT Pharmacometrics Syst Pharmacol | 2026 | https://conductscience.org/library/papers/41347637 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41347637
GET https://conductscience.org/api/papers/v1/41347637/references?page=2